Quick Answer
Lexeo Therapeutics, Inc. reported R&D Expense of $63.80 million for fiscal year 2025.
Lexeo Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $63.80M | -13.9% |
| 2024 | $74.09M | +39.5% |
| 2023 | $53.13M | +8.1% |
| 2022 | $49.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.70M | -33.0% | +6.6% |
| June 30, 2025 | $14.72M | -11.1% | -14.3% |
| March 31, 2025 | $17.17M | +9.1% | -26.7% |
| September 30, 2024 | $23.42M | +35.8% | +41.4% |
| June 30, 2024 | $16.56M | +47.4% | +5.2% |
| March 31, 2024 | $15.74M | -4.2% | -8.7% |
| September 30, 2023 | $17.25M | +12.3% | +53.5% |
| June 30, 2023 | $11.24M | — | -31.6% |
- Lexeo Therapeutics, Inc. showed a decrease of -13.9% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, Lexeo Therapeutics, Inc.’s r&d expense has grown by 29.8% (from $49.16 million to $63.80 million).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: